Land: Malaysia
Språk: engelska
Källa: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
CINNARIZINE
JOHNSON & JOHNSON SDN BHD
CINNARIZINE
250Tablet Tablets; 50 Tablets
JANSSEN CILAG SPA
_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP) _ STUGERON ® TABLET Cinnarizine ( 25mg) 1 WHAT IS IN THIS LEAFLET 1. What STUGERON ® is used for 2. How STUGERON ® works 3. Before you use STUGERON ® 4. How to use STUGERON ® 5. While you are using it 6. Side effects 7. Storage and disposal of STUGERON ® 8. Product description 9. Manufacturer and product registration holder 10. Date of revision 11. Serial number WHAT STUGERON ® IS USED FOR STUGERON ® is used to treat the following: • BALANCE DISORDERS – STUGERON ® relieves the dizziness and spinning sensation (‘vertigo’) caused by problems of the inner ear. It also relieves the associated symptoms, like persistent ringing in the ears (‘tinnitus’), rapid and uncontrollable movements of the eyes, nausea and vomiting; STUGERON ® also PREVENTS MOTION SICKNESS. HOW STUGERON ® WORKS The medicine in STUGERON ® is cinnarizine that helps symptoms caused by balance or movement problems. BEFORE YOU USE STUGERON ® - _When you must not use it _ Do not take STUGERON ® tablets if: • You are allergic to cinnarizine or any of the other ingredients in STUGERON ® tablets (listed in “Product Description – Ingredients”) • Your child is under 5 years old Do not take this medicine if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking STUGERON ® tablets. - _Pregnancy and breastfeeding _ If you are pregnant or plan to be pregnant, inform your doctor, who will decide if you can take STUGERON ® . STUGERON ® should be used during pregnancy only if the therapeutic benefits justify the potential risks for the fetus. If you are taking STUGERON ® , you are advised not to breastfeed since there is no data on the excretion of STUGERON ® in human breast milk. - _Before you start to use it _ _Parkinson's disease _ If you have Parkinson's disease, tell your doctor, who will decide if you can take STUGERON ® . - _Taking other medicines _ Medicines for depression and medicines that slow up your reactions (sleep Läs hela dokumentet
1 PRODUCT NAME STUGERON ® (cinnarizine) DOSAGE FORMS AND STRENGTH Tablets. White, circular, halfscored tablet with the inscription “JANSSEN” on one side and “S/25” on the other side. Each tablet contains 25 mg cinnarizine. For excipients, see List of Excipients. CLINICAL INFORMATION INDICATIONS • Disorders of balance - maintenance therapy for symptoms of labyrinthine disorders, including vertigo, dizziness, tinnitus, nystagmus, nausea and vomiting. • Prophylaxis of motion sickness. DOSAGE AND ADMINISTRATION _DOSAGE _ _Disorders of balance_ - Adult • 1 tablet of 25 mg three times a day _Prophylaxis of motion sickness_ : • Adults and adolescents aged 13 years and above: 1 tablet of 25 mg at least half an hour before travelling; to be repeated every 6 hours; • Children aged 6 to 12 years: half of the adult dose is recommended. _ADMINISTRATION _ STUGERON ® should preferably be taken after meals. It is for oral administration. CONTRAINDICATIONS STUGERON ® is contraindicated in patients with known hypersensitivity to the drug. WARNINGS AND PRECAUTIONS As with other antihistamines STUGERON ® may cause epigastric distress; taking it after meals may diminish gastric irritation. In patients with Parkinson’s disease STUGERON ® should only be given if the advantages outweigh the possible risk of aggravating this disease. STUGERON ® may cause somnolence, especially at the start of treatment. Therefore caution should be taken when alcohol, central nervous system (CNS) depressants or tricyclic antidepressants are used concomitantly. INTERACTIONS _Alcohol/CNS Depressants and tricyclic antidepressants _ The sedative effects of STUGERON ® and of any of the following may be potentiated when used concomitantly: alcohol, CNS depressants, or tricyclic antidepressants. 2 _ _ _Diagnostic interference _ Because of its antihistamine effect, STUGERON ® may prevent otherwise positive reactions to dermal reactivity indicators if used up to 4 days prior to skin testing. _ _ PREGNANCY AND BREAST-FEEDING _Pregnancy _ Läs hela dokumentet